Search results for "OUTCOME"

showing 10 items of 5148 documents

Evidenz für eine frühzeitige Therapie der COPD mit Tiotropium

2012

Hintergrund: Die Wirksamkeit von Tiotropium versus Kontrolle wurde in einer praspezifizierten Subgruppenanalyse der 4-Jahres-Studie „Understanding Potential Long-term Impacts on Function with Tiotropium“ bei Patienten mit chronisch obstruktiver Lungenerkrankung (COPD) mittleren Schweregrades (GOLD II) untersucht und erstmals den gepoolten Ergebnissen aus den schwereren Krankheitsstadien (GOLD III/IV) gegenubergestellt. Methode: Randomisierte multizentrische, doppelblinde, kontrollierte Studie mit parallelem Gruppenvergleich bei 5993 Patienten uber 4 Jahre. Die Patienten erhielten entweder Tiotropium 18 µg einmal taglich oder Plazebo. Als Endpunkte wurden der jahrliche FEV1-Abfall und weiter…

Pulmonary and Respiratory MedicineSecondary preventionGynecologymedicine.medical_specialtyCOPDbusiness.industryTreatment outcomemedicinePulmonary diseaseTiotropium bromidebusinessmedicine.diseasemedicine.drugPneumologie
researchProduct

Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe…

2021

Background: ANDHI was done to assess the efficacy of benralizumab, including onset of effect and impact on health-related quality of life (HRQOL), exacerbation rate, lung function, and nasal polyposis symptoms. Methods: This phase 3b, randomised, double-blind, parallel-group, placebo-controlled ANDHI study was completed in adults (aged 18–75 years) with severe eosinophilic asthma with at least 2 exacerbations in the previous year, despite high-dose inhaled corticosteroid plus additional controllers, screening blood eosinophil counts of at least 150 cells per μL, and an Asthma Control Questionnaire 6 (ACQ-6) score of 1·5 or more. Patients who met eligibility criteria were randomly assigned (…

Pulmonary and Respiratory MedicineSpirometryAdultMalemedicine.medical_specialtyExacerbation[SDV]Life Sciences [q-bio]PopulationSettore MED/10 - Malattie Dell'Apparato RespiratorioPlaceboAntibodies Monoclonal Humanized03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDouble-Blind MethodInternal medicinemedicineHumans030212 general & internal medicineAnti-Asthmatic AgentsPatient Reported Outcome MeasureseducationSinusitisAsthmaeducation.field_of_studymedicine.diagnostic_testbusiness.industryMiddle Agedmedicine.diseaseBenralizumabAsthma3. Good healthEosinophils030228 respiratory systemchemistryAsthma Control QuestionnaireSpirometryDisease ProgressionQuality of LifeFemalebusiness
researchProduct

Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD.

2011

Two, once daily (q.d.) inhaled bronchodilators are available for the treatment of chronic obstructive pulmonary disease (COPD): the β(2)-agonist indacaterol and the anticholinergic tiotropium. This blinded study compared the efficacy of these two agents and assessed their safety and tolerability. Patients with moderate-to-severe COPD were randomised to treatment with indacaterol 150 μg q.d. (n=797) or tiotropium 18 μg q.d. (n=801) for 12 weeks. After 12 weeks, the two treatments had similar overall effects on "trough" (24 h post-dose) forced expiratory volume in 1 s. Indacaterol-treated patients had greater improvements in transition dyspnoea index (TDI) total score (least squares means 2.0…

Pulmonary and Respiratory MedicineSpirometryMalemedicine.drug_classScopolamine DerivativesQuinolonesSeverity of Illness IndexCholinergic AntagonistsDrug Administration ScheduleMedical Recordslaw.inventionPulmonary Disease Chronic ObstructiveRandomized controlled trialDouble-Blind MethodlawAdrenergic beta-2 Receptor AntagonistsForced Expiratory VolumemedicineAnticholinergicHumansTiotropium BromideAdverse effectAgedCOPDmedicine.diagnostic_testbusiness.industryTiotropium bromideMiddle Agedmedicine.diseaserespiratory tract diseasesBronchodilator AgentsTreatment OutcomeTolerabilitySpirometryAnesthesiaIndansIndacaterolFemalebusinessmedicine.drugThe European respiratory journal
researchProduct

Alternative ways of expressing FEV1 and mortality in elderly people with and without COPD

2013

Expressing forced expiratory volume in 1 s (FEV1) as % predicted relies on the assumption of proportional variability and generalisability of prediction equations that may be unrealistic, especially for elderly people. We evaluated the prognostic implications of alternative ways of expressing FEV1. We enrolled 318 patients with chronic obstructive pulmonary disease (COPD) and 475 controls in the Salute Respiratoria nell'Anziano (SARA) study. The risk for 5-, 10- and 15-year mortality associated with FEV1 was studied by expressing FEV1 % pred, standardised by height cubed (FEV1 · Ht(-3)) and as a multiple of the sex-specific first percentile (FEV1 quotient (FEV1Q)). In the group with COPD, t…

Pulmonary and Respiratory MedicineSpirometryMalemedicine.medical_specialtyPediatricsPercentilePrognosiPulmonary diseaseSettore MED/10 - Malattie Dell'Apparato RespiratorioRate ratioPulmonary Disease Chronic ObstructiveElderly populationInternal medicineForced Expiratory VolumeHumansMedicineElderly peopleRespiratory Function TestAgedCOPDmedicine.diagnostic_testbusiness.industryRespiratory Function Tests; Spirometry; Humans; Treatment Outcome; Prognosis; Case-Control Studies; Aged; Middle Aged; Forced Expiratory Volume; Male; Female; Pulmonary Disease Chronic ObstructiveCase-control studyrespiratory systemMiddle AgedPrognosismedicine.diseaseRespiratory Function Testsrespiratory tract diseasesTreatment OutcomeSpirometryCase-Control StudiesFemalebusinessCase-Control StudieHuman
researchProduct

Successful surgery of neuroendocrine carcinoma infiltrating right ventricle and pulmonary artery.

2020

We present the clinical case of a 60-year-old woman complained of dyspnea on exertion. Echocardiogram showed a giant mass in the right ventricle (RV) with obstruction to the outflow tract. Thorax computed tomography confirmed a mass of greater than 60 mm infiltrating RV and causing severe stenosis in the pulmonary artery, with severe pericardial effusion. Cardiac surgery was performed for tumor resection and pulmonary root replacement with a biological valved conduit. Histological analysis diagnosed a poorly differentiated large-cell neuroendocrine carcinoma. The patient had no immediate postoperative complications and has completed radiotherapy at a 9-month follow-up.

Pulmonary and Respiratory MedicineThoraxmedicine.medical_specialtymedicine.medical_treatmentHeart VentriclesConstriction Pathologic030204 cardiovascular system & hematologyPulmonary ArteryPericardial effusionSeverity of Illness IndexPericardial EffusionHeart Neoplasms03 medical and health sciencesBlood Vessel Prosthesis Implantation0302 clinical medicinemedicine.arterymedicineHumansNeuroendocrine carcinomaExertionCardiac Surgical Proceduresbusiness.industryMiddle Agedmedicine.diseaseSurgeryCardiac surgeryCarcinoma NeuroendocrineRadiation therapymedicine.anatomical_structureTreatment Outcome030228 respiratory systemVentricleEchocardiographyPulmonary arterySurgeryFemaleCardiology and Cardiovascular MedicinebusinessTomography X-Ray ComputedJournal of cardiac surgeryREFERENCES
researchProduct

Endovascular treatment of acute bleeding complications in traumatic aortic rupture and aortobronchial fistula.

2001

Objective: Herein we report our experience in placement of endovascular stentgrafts in the descending aorta in patients with acute bleeding complications due to traumatic rupture or aortobronchial fistula. Methods: Six patients (one woman, five men, mean age 47 ^ 19 years) were treated from September 1995 to February 2000 by implantation of endovascular stentgrafts in the descending aorta. Indications included traumatic ruptures of the aortic isthmus (na 3) and aortobronchial fistulas (na 3). All procedures were performed under general anaesthesia. The implants were introduced under fluoroscopic guidance via the aorta (na 1), the iliac (na 4) or femoral (na 2) artery, respectively. Results:…

Pulmonary and Respiratory MedicineTraumatic aortic ruptureAdultMalemedicine.medical_specialtyFistulaFistulamedicine.medical_treatmentAortic RuptureAortic DiseasesAorta ThoracicHemorrhageRecurrencemedicine.arterymedicineHumansMinimally Invasive Surgical ProceduresAortic ruptureAgedVascular FistulaAortabusiness.industryStentGeneral MedicinePerioperativeMiddle Agedmedicine.diseaseSurgeryRadiographyTreatment OutcomeCardiothoracic surgeryDescending aortaAcute DiseaseSurgeryFemaleRadiologyBronchial FistulaCardiology and Cardiovascular MedicinebusinessEuropean journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
researchProduct

Dose bridging data for mometasone furoate in once-daily fixed-dose inhaled combinations of mometasone furoate/indacaterol and mometasone furoate/ ind…

2021

Once-daily (o.d.) fixed-dose combinations of mometasone furoate/indacaterol acetate (MF/IND) and mometasone furoate/indacaterol acetate/glycopyrronium bromide (MF/IND/GLY), both delivered via the Breezhaler® device, are approved for the maintenance treatment of asthma. Across these fixed-dose combinations, while the doses of bronchodilators remain the same, the nominal doses of mometasone furoate in micrograms differ. This article presents the steps followed in bridging the mometasone furoate doses at the corresponding dose strengths in the mometasone furoate formulation delivered via the Twisthaler® and mometasone furoate/indacaterol acetate and mometasone furoate/indacaterol acetate/glyco…

Pulmonary and Respiratory Medicinemedicine.drug_classMometasone furoateQuinolonesPharmacologyFixed doseAdministration InhalationHumansMedicinePharmacology (medical)In patientGlycopyrronium bromideAsthmabusiness.industryBiochemistry (medical)medicine.diseaseGlycopyrrolateAsthmaBronchodilator AgentsDrug CombinationsTreatment OutcomeIndansIndacaterolCorticosteroidOnce dailybusinessMometasone Furoatemedicine.drugPulmonary Pharmacology & Therapeutics
researchProduct

Prediction of mortality rate in acute type A dissection: the German Registry for Acute Type A Aortic Dissection score.

2020

Abstract OBJECTIVES The goal was to develop a scoring system to predict the 30-day mortality rate for patients undergoing surgery for acute type A aortic dissection on the basis of the German Registry for Acute Type A Aortic Dissection (GERAADA) data set and to provide a Web-based application for standard use. METHODS A total of 2537 patients enrolled in GERAADA who underwent surgery between 2006 and 2015 were analysed. Variable selection was performed using the R-package FAMoS. The robustness of the results was confirmed via the bootstrap procedure. The coefficients of the final model were used to calculate the risk score in a Web-based application. RESULTS Age [odds ratio (OR) 1.018, 95% …

Pulmonary and Respiratory Medicinemedicine.medical_specialty030204 cardiovascular system & hematologyPreoperative care03 medical and health sciences0302 clinical medicinePostoperative ComplicationsRisk FactorsMedicineHumansddc:610RegistriesAortic dissectionFramingham Risk Scorebusiness.industryMortality rateDissectionGeneral MedicineOdds ratiomedicine.diseaseConfidence intervalSurgeryCardiac surgeryAortic AneurysmDissectionAortic DissectionTreatment Outcome030228 respiratory systemAcute DiseaseSurgeryCardiology and Cardiovascular MedicinebusinessEuropean journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
researchProduct

Effectiveness and safety of concurrent beta-blockers and inhaled bronchodilators in COPD with cardiovascular comorbidities

2017

Chronic obstructive pulmonary disease (COPD) is the most common chronic respiratory disease and its prevalence is increasing worldwide, in both industrialised and developing countries. Its prevalence is ∼5% in the general population and it is the fourth leading cause of death worldwide. COPD is strongly associated with cardiovascular diseases; in fact, ∼64% of people suffering from COPD are treated for a concomitant cardiovascular disease and approximately one in three COPD patients die as a consequence of cardiovascular diseases.Inhaled bronchodilators might have adverse cardiovascular effects, including ischaemic events and arrhythmias, and beta-blockers might adversely influence the resp…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyAdrenergic beta-AntagonistsPopulationComorbidityDiseaseRisk AssessmentPulmonary Disease Chronic Obstructive03 medical and health sciences0302 clinical medicineRisk FactorsAdministration InhalationEpidemiologymedicineHumans030212 general & internal medicineeducationIntensive care medicineLungCause of deathlcsh:RC705-779education.field_of_studyCOPDbusiness.industryRespiratory diseaselcsh:Diseases of the respiratory systemmedicine.diseaseComorbidityBronchodilator AgentsTreatment Outcome030228 respiratory systemCardiovascular DiseasesbusinessRisk assessmentEuropean Respiratory Review
researchProduct

The mutual relationship between heart failure and atrial fibrillation

2020

Atrial fibrillation (AF) and heart failure (HF) are evolving epidemies, together responsible for substantial human suffering and health-care expenditure. The simultaneous co-hexistence of the two conditions is associated with mortality rates higher than those observed in individuals with only one or none of them. Patients with concomitant HF and AF suffer from even worse symptoms and poorer prognosis, yet evidence-based evaluation and management of this group of patients is lacking. In this review, we evaluate the common mechanisms for the development of AF in HF patients and vice versa, focusing on the evidence for potential treatment strategies. Recent data have suggested that these patie…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyAdverse outcomesbusiness.industryMortality ratelcsh:Rheart failurelcsh:MedicineAtrial fibrillationArrhythmia-induced cardiomyopathymedicine.diseaseAtrial fibrillationHeart failure.Risk FactorsHeart failureConcomitantmedicineHumansTreatment strategyBest evidenceCardiology and Cardiovascular MedicineIntensive care medicinebusinessHealthcare system
researchProduct